- ￥750 - 3647
- MedChemExpress(MCE)
- 美国
- HY-137506
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
2607143-50-8
- 规格：
10 mM * 1 mL/5 mg/10 mg/25 mg/50 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥825.0 |
|---|---|---|---|
| 规格： | 5 mg | 产品价格： | ￥750.0 |
| 规格： | 10 mg | 产品价格： | ￥1199.0 |
| 规格： | 25 mg | 产品价格： | ￥2279.0 |
| 规格： | 50 mg | 产品价格： | ￥3647.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
XST-14
CAS No. : 2607143-50-8
MCE 国际站：XST-14
产品活性：XST-14 是一种有效的，竞争性强且高度选择性的 ULK1 抑制剂，IC50 为 26.6 nM。XST-14 通过减少 ULK1 下游底物的磷酸化来诱导自噬抑制。XST-14 诱导肝细胞癌 (HCC) 细胞凋亡，并具有抗肿瘤作用。
研究领域：Autophagy | MAPK/ERK Pathway | TGF-beta/Smad | Protein Tyrosine Kinase/RTK | Neuronal Signaling | Apoptosis
作用靶点：ULK | p38 MAPK | TGF-β Receptor | Anaplastic lymphoma kinase (ALK) | CaMK | Apoptosis
In Vitro: XST-14 inhibits ULK1 (IC50=13.6 nM), MAP2K1/MEK1 (IC50=721.8 nM), MAPK14/p38 alpha (IC50=283.9 nM), TGFBR2 (IC50=809.3 nM), ACVR1/ALK2 (IC50=183.8 nM), ULK2 (IC50=70.9 nM) and CAMK2A (IC50=66.3 nM) by the 10-point titration results from SelectScreen Kinase Profiling Services.
XST-14 (20-80 μM; for 24 h) leads a decrease in cell proliferation activity.
XST-14 (5 μM; for 24 h) induces apoptosis in HepG2 and human primary HCC cells.
XST-14 (5 μM; for 12 h) strongly inhibits the conversion of LC3-I to LC3-II in CHO cells stably expressing GFP-LC3.
XST-14 (5 μM; for 12 h) inhibits the Ser249 phosphorylation of PIK3C3 and Ser15 phosphorylation of BECN1.
In Vivo: XST-14 (15, 30 mg/kg/day; IP; for 4 consecutive weeks) displays anti-HCC efficacies, resulting in decreased tumor weights and suppressed tumor growth of HCC cells in nude mice.
XST-14 (2 mg/kg for IV; 10 mg/kg for IP) has a T1/2 of 2.31 hours for IV and a T1/2 of 2.69 hours for IP.
相关产品：Bioactive Compound Library Plus | Apoptosis Compound Library | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Neuronal Signaling Compound Library | Protein Tyrosine Kinase Compound Library | TGF-beta/Smad Compound Library | Anti-Cancer Compound Library | Autophagy Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Pyroptosis Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Neurodegenerative Disease-related Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Antidepressant Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Osteogenesis Compound Library | Cancer Stem Cells Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cytokine Inhibitors Library | Cell Death Library | Serine/Threonine Kinase Inhibitor Library | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Dorsomorphin | Sorafenib | Oxaliplatin | Gemcitabine | Temozolomide | Adezmapimod | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib | Decitabine | SP600125 | MK-2206 dihydrochloride
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验《麻省理工科技评论》发布 50 大创新公司，生物公司有 14 家
《麻省理工科技评论》创刊于 1899 年，是世界上历史最悠久、影响力最大的技术商业类杂志，现已发展为具有全球影响力的数字化平台。 每年，《麻省理工科技评论》都会评选出 50 家最具创新力的公司，它们在各自的行业中创造了全新的机遇。入选 2016 年 50 大创新公司的明星中，有些是诸如亚马逊、百度、华为等大公司，也有一些生物公司，我们一起来看看。 1.Illumina Illumina 公司总部位于加州，目前
3.73 3.61 3.51 3.44 3.37 3.28 3.18 3.07 2.96 2.85 2.72 12 13 4.96 4.35 4.00 3.77 3.60 3.48 3.39 3.31 3.25 3.15 3.05 2.95 2.84 2.72 2.59 13 14 4.86 4.24 3.89 3.66 3.50 3.38 3.28 3.21 3.15 3.05 2.95 2.84 2.73 2.61 2.49 14 15 4.76 4.15 3.80
Cancer Cell：中山大学刘卓炜团队揭示膀胱癌成纤维细胞新亚群介导肿瘤干性和化疗抵抗
膀胱癌是泌尿系统中最常见的恶性肿瘤。虽然近年来免疫治疗，靶向治疗等多种治疗不断涌现，但目前以顺铂为基础的化疗在进展期膀胱癌的治疗中仍有不可撼动的地位。然而，目前膀胱癌患者的化疗有效率仅为 50% 左右，许多患者在综合治疗后仍会出现肿瘤的迅速进展并最终导致患者死亡【1】。因此，如何提高中、晚期膀胱癌患者的化疗疗效是一个亟待解决的问题。 癌症相关成纤维细胞（CAF）是肿瘤免疫微环境中最丰富的间质细胞，其在介导肿瘤发生发展、治疗抵抗、免疫抑制的过程中发挥着重要的功能。近年来的研究发现 CAF
技术资料暂无技术资料 索取技术资料
